<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acute myeloid leukemia in younger adults: Post-remission therapy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acute myeloid leukemia in younger adults: Post-remission therapy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acute myeloid leukemia in younger adults: Post-remission therapy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard A Larson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bob Lowenberg, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 23, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sixty to 80 percent of adult patients with newly diagnosed acute myeloid leukemia (AML) will attain a complete remission (CR) with intensive induction chemotherapy. However, without additional cytotoxic therapy, virtually all of these patients will relapse within a median of four to eight months [
         <a href="#rid1">
          1
         </a>
         ]. In contrast, patients who receive post-remission therapy may expect four-year survival rates as high as 40 percent in young and middle-aged adults.
        </p>
        <p>
         Post-remission therapy aims to destroy leukemia cells that survived induction chemotherapy but are undetectable by conventional studies. There are three basic options for post-remission therapy (in order of increasing intensity): consolidation chemotherapy, autologous hematopoietic cell transplantation (HCT), or allogeneic HCT. The choice among these approaches for an individual patient depends on a number of factors including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Expected rate of relapse with consolidation chemotherapy alone (influenced strongly by the tumor karyotype)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Expected morbidity and mortality associated with treatment options (as determined by patient characteristics such as age and comorbidities)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Salvage treatments available for the treatment of relapsed disease
        </p>
        <p>
        </p>
        <p>
         This approach minimizes exposure to potentially toxic therapies in patients expected to respond well to conventional chemotherapy while providing maximum antitumor activity for patients with more difficult-to-treat disease.
        </p>
        <p>
         Post-remission therapy for AML in younger adults will be reviewed here. Induction therapy is presented separately, as are the treatment of relapsed disease and the management of complications related to AML. (See
         <a class="medical medical_review" href="/z/d/html/4525.html" rel="external">
          "Acute myeloid leukemia: Induction therapy in medically fit adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4540.html" rel="external">
          "Treatment of relapsed or refractory acute myeloid leukemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4510.html" rel="external">
          "Acute myeloid leukemia: Overview of complications"
         </a>
         .)
        </p>
        <p>
         Among patients with AML, treatment regimens and outcomes may differ between younger and older adults. Although there is no clear dividing line between younger and older adults when dealing with AML, "older adults" was defined as over age 60 in most studies. The treatment of older adults is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4530.html" rel="external">
          "Acute myeloid leukemia: Management of medically unfit adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          RISK STRATIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is strongly recommended that every case of newly diagnosed AML undergo cytogenetic and molecular analysis before starting induction therapy, since specific cytogenetic abnormalities in AML have considerable prognostic significance [
         <a href="#rid2">
          2-4
         </a>
         ]. Results from cytogenetic and molecular analyses are essential for World Health Organization (WHO) classification of AML  (
         <a class="graphic graphic_table graphicRef110239" href="/z/d/graphic/110239.html" rel="external">
          table 1
         </a>
         ). Full knowledge of the karyotype determined by metaphase cytogenetics is an essential part of treatment planning and monitoring of the leukemic clone. More recently, information about the genotype based on molecular studies has demonstrated prognostic significance that can be used to guide treatment decisions as well. (See
         <a class="medical medical_review" href="/z/d/html/4525.html" rel="external">
          "Acute myeloid leukemia: Induction therapy in medically fit adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4516.html" rel="external">
          "Acute myeloid leukemia: Risk factors and prognosis", section on 'Cytogenetics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Stratification by genetic risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         Knowledge of the cytogenetic and molecular abnormalities associated with AML has led to various risk stratification schemata. We prefer the system for risk stratification developed by the European LeukemiaNet (ELN) that describes three risk categories (ie, favorable, intermediate, adverse)  (
         <a class="graphic graphic_table graphicRef111588" href="/z/d/graphic/111588.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]. Stratification models that incorporate genetic abnormalities (eg, ELN, WHO) are dynamic and evolving as better understanding of the genetic basis of AML emerges and as additional clinical outcome data become available. Such schemata will result in smaller but more homogeneous subsets of patients with AML, and may increasingly inform therapeutic choices that will involve targeted therapies.
        </p>
        <p>
         Further details of the prognostic value of various karyotypic and molecular features in AML are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4544.html" rel="external">
          "Acute myeloid leukemia: Cytogenetic abnormalities"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4516.html" rel="external">
          "Acute myeloid leukemia: Risk factors and prognosis", section on 'Cytogenetics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          FAVORABLE-RISK DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         While the optimal dose, schedule, and number of cycles are unknown, consolidation chemotherapy with high dose
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         (HiDAC) appears to provide the best survival for most patients with favorable-risk disease with the least amount of toxicity. This approach results in overall survival rates at four years of 60 to 75 percent. A randomized trial indicated a disease-free survival benefit when
         <a class="drug drug_general" data-topicid="8968" href="/z/d/drug information/8968.html" rel="external">
          gemtuzumab ozogamicin
         </a>
         was incorporated into induction and post-remission phases of treatment for patients with core-binding factor AML [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="local">
          'Administration of consolidation HiDAC'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Chemotherapy versus transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many prospective studies have investigated the use of various post-remission therapies in patients with favorable-risk disease including chemotherapy alone, autologous hematopoietic cell transplantation (HCT), allogeneic HCT, and maintenance therapy. Randomized trials of allogeneic HCT have not been feasible for patients with AML. Instead, investigators have relied on a "genetic randomization" in which patients are assigned to treatment with or without allogeneic HCT based on the presence or absence of an HLA-matched sibling donor. Patients without an HLA-matched sibling are assigned to treatment with either chemotherapy alone or autologous HCT, depending on the trial design. Results are then evaluated by an intention-to-treat analysis for "donor" and "no donor" (available) treatment groups. As with randomized trials, not all patients in the "donor" group ultimately receive an allogeneic HCT, but they would still be included in the "donor" group for the statistical analysis.
        </p>
        <p>
         Three large meta-analyses of these studies performed using data from over 4000 patients with AML in first complete remission (CR) examined the effect of donor availability and cytogenetic risk category on disease-free and overall survival [
         <a href="#rid6">
          6-8
         </a>
         ]. There were 480 patients with favorable-risk disease analyzed. In this group, the availability of an HLA-matched sibling did not result in superior disease-free or overall survival, implying no benefit from allogeneic HCT in this risk group. The estimated risk of relapse after consolidation chemotherapy is approximately 35 percent or less in this population. With such a relatively low risk of relapse, the high rate of treatment-related mortality associated with allogeneic HCT (approximately 20 percent) likely negates the effect of a possible small decrease in relapse rate on disease-free or overall survival. A randomized trial also demonstrated that consolidation chemotherapy results in superior survival rates when compared with lower dose maintenance therapy given over an extended period of time [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         A decision regarding the use of allogeneic HCT in first remission must also consider the estimated rate of relapse and the efficacy of available treatments at the time of relapse. In one analysis, 494 of 536 younger adults (16 to 49 years) with favorable-risk AML enrolled on prospective trials did not proceed with HCT in their first CR [
         <a href="#rid10">
          10
         </a>
         ]. The 168 (34 percent) patients who relapsed following chemotherapy alone had an estimated five-year survival following relapse of 32 percent. These findings suggest that a significant percentage of patients with favorable-risk disease who defer initial HCT can be effectively treated following relapse. HLA typing should be included in the initial evaluation of these patients to expedite the donor search if the patient relapses.
        </p>
        <p>
         For young patients with newly diagnosed AML demonstrating favorable cytogenetics, we recommend post-remission therapy with consolidation chemotherapy rather than either autologous HCT or allogeneic HCT. Post-remission chemotherapy is used in this patient population instead of HCT to avoid the unnecessary risks of acute and chronic morbidity and mortality associated with HCT in a considerable number of patients who may be cured with consolidation chemotherapy alone. HCT is then reserved for use at the time of relapse, if necessary. (See
         <a class="medical medical_review" href="/z/d/html/4540.html" rel="external">
          "Treatment of relapsed or refractory acute myeloid leukemia", section on 'Hematopoietic cell transplantation'
         </a>
         .)
        </p>
        <p>
         Controversy remains as to whether allogeneic HCT in first CR is of benefit in patients with normal karyotypes that demonstrate certain gene mutations. The European LeukemiaNet classification's favorable risk subgroup includes the following two groups with normal cytogenetics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with normal cytogenetics displaying mutations in both alleles of the nucleophosmin 1 (
         <em>
          NPM1
         </em>
         ) gene but lacking coexistent FMS-like tyrosine kinase 3 gene producing internal transmembrane duplications (
         <em>
          FLT3
         </em>
         -ITD) mutations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with normal cytogenetics displaying mutations in the CCAAT/enhancer binding protein alpha (
         <em>
          CEBPA
         </em>
         ) gene.
        </p>
        <p>
        </p>
        <p>
         Support for the use of consolidation chemotherapy in this population comes from the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subjects with a normal karyotype,
         <em>
          NPM1
         </em>
         mutations, wild-type
         <em>
          FLT3
         </em>
         , and low levels of
         <em>
          ERG
         </em>
         appear to have an especially favorable prognosis, with an estimated two-year progression-free survival of 60 to 70 percent after induction treatment with
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9326" href="/z/d/drug information/9326.html" rel="external">
          daunorubicin
         </a>
         , and
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         followed by high dose cytarabine or autologous HCT [
         <a href="#rid11">
          11,12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Data from "donor" versus "no donor" analyses demonstrate that a subgroup of cytogenetically normal AML defined by the favorable molecular genotype with
         <em>
          NPM1
         </em>
         gene mutations but no
         <em>
          FLT3
         </em>
         -ITD mutations have outcomes similar to those patients with favorable karyotypes [
         <a href="#rid12">
          12,13
         </a>
         ]. Such patients derive no overall survival benefit from allogeneic HCT in first CR compared with chemotherapy alone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective analysis of 124 patients with double mutant
         <em>
          CEBPA
         </em>
         from cooperative group trials, relapse-free survival was higher following allogeneic HCT (hazard ratio 0.23; 95% CI 0.11-0.51) or autologous HCT (0.37; 95% CI 0.17-0.80) rather than consolidation chemotherapy [
         <a href="#rid14">
          14
         </a>
         ]. However, this improved relapse-free survival did not translate into an overall survival benefit, largely due to a high rate of second CR and survival after allogeneic HCT at the time of relapse.
        </p>
        <p>
        </p>
        <p>
         Thus, a subset of patients with normal karyotype may not require an allogeneic HCT. Given the controversy surrounding this group of patients, patients should be encouraged to participate in clinical trials. Outside of a clinical trial, any of the above approaches may be offered.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Choice of agent
         </span>
         <span class="headingEndMark">
          —
         </span>
         High dose
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         (HiDAC) has been the consolidation chemotherapy of choice in patients with favorable-risk disease for more than two decades. Attempts to improve survival rates over those attained with HiDAC by altering the dose or schedule of cytarabine, substituting other agents, or other drug combinations have shown similar efficacy [
         <a href="#rid2">
          2,15-23
         </a>
         ].
        </p>
        <p>
         Trials using alternating courses of other drug combinations have demonstrated similarly favorable outcomes, and offer equally effective alternative options. Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized study of 473 patients &lt;60 years of age, the use of three consolidation courses of HiDAC was equally effective as three courses of sequential multiagent chemotherapy (one course each of HiDAC,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         /
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , and diaziquone/
         <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">
          mitoxantrone
         </a>
         ), with less overall toxicity [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A phase 3 trial of 293 patients (&lt;60 years of age; most with intermediate-risk cytogenetics) reported improved leukemia-free survival, but not overall survival, among those who received more intensive
         <a class="drug drug_general" data-topicid="8549" href="/z/d/drug information/8549.html" rel="external">
          idarubicin
         </a>
         (9 mg/m
         <sup>
          2
         </sup>
         daily for three days versus two days) as a component of two cycles of consolidation therapy that also included five days each of
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         100 mg/m
         <sup>
          2
         </sup>
         daily and
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         75 mg/m
         <sup>
          2
         </sup>
         daily [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Dose of cytarabine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          Cytarabine
         </a>
         is one of the most effective agents available for the treatment of AML and is a key component of induction therapy. HiDAC produces high intracellular drug concentrations, which saturate the deaminating metabolic enzyme pathway, leading to increased levels of the active agent ara-cytidine triphosphate. In this way, HiDAC can often effectively eliminate measurable residual disease (MRD; also referred to as minimal residual disease) that survived induction with cytarabine containing regimens.
        </p>
        <p>
         A variety of HiDAC doses and schedules have been used in clinical trials [
         <a href="#rid25">
          25
         </a>
         ]. Higher doses of
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         are preferable to lower doses (as described below), but the ideal dose remains unknown and there is likely a dose above which additional cytarabine is not of benefit. A cytarabine dose of 3 g/m
         <sup>
          2
         </sup>
         given over three hours is frequently used, but cytarabine 1 to 1.5 g/m
         <sup>
          2
         </sup>
         twice daily for five days has demonstrated similar rates of disease-free and overall survival; these regimens have not been compared directly in a prospective trial [
         <a href="#rid17">
          17
         </a>
         ]. There was no difference in five-year overall survival when young patients (age 15 to 60) were randomly assigned to consolidation therapy with cytarabine 3 g/m
         <sup>
          2
         </sup>
         twice daily for six days versus cytarabine 1 g/m
         <sup>
          2
         </sup>
         twice daily for six days (both cytarabine doses combined with
         <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">
          mitoxantrone
         </a>
         for a first consolidation course, followed in some cases by an autologous or allogeneic transplant) [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         Consolidation chemotherapy with HiDAC produces superior survival rates than those seen with lower doses of
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         . This was principally demonstrated in a randomized trial of consolidation therapy in 596 patients using 4 courses of cytarabine at low (100 mg/m
         <sup>
          2
         </sup>
         per day) or intermediate doses (400 mg/m
         <sup>
          2
         </sup>
         per day) as continuous IV infusions for 5 days or at high doses (HiDAC: 3 g/m
         <sup>
          2
         </sup>
         every 12 hours on days 1, 3, and 5) [
         <a href="#rid26">
          26
         </a>
         ]. Patients &lt;60 years old who received HiDAC had the following significant outcomes when compared with patients who received intermediate or low dose cytarabine:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher rates of four-year disease-free survival (44 versus 29 and 24 percent, respectively)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improved four-year overall survival rates (52 versus 40 and 35 percent, respectively)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fewer relapses more than two years after attaining complete remission (44 versus 29 and 24 percent, respectively)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Greater toxicity (see
         <a class="local">
          'Toxicities'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Number of cycles
         </span>
         <span class="headingEndMark">
          —
         </span>
         The ideal number of post-remission chemotherapy cycles is not known, but patients who receive at least three cycles appear to do better than those who receive fewer.
        </p>
        <p>
         As an example, a total of 50 patients with AML and t(8;21)(q22;q22) from four successive CALGB studies were assigned (but not randomized) to receive either one (29 patients) or ≥3 cycles (21 patients) of HiDAC as post-induction therapy [
         <a href="#rid27">
          27
         </a>
         ]. When compared with those receiving a single cycle of HiDAC, patients treated with ≥3 cycles of HiDAC demonstrated:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A lower rate of relapse – 19 versus 62 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Longer median relapse-free survival – &gt;35 versus 10.5 months
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A higher estimated rate of five-year overall survival – 76 versus 44 percent
        </p>
        <p>
        </p>
        <p>
         A similar report using data from AML patients with inv(16) or t(16;16) found that repetitive HiDAC therapy decreases the likelihood of relapse compared with consolidation regimens including less HiDAC [
         <a href="#rid28">
          28
         </a>
         ]. However, there was no significant difference in overall survival, likely due to a high success rate using salvage treatment with hematopoietic cell transplantation in relapsing patients.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Administration of consolidation HiDAC
         </span>
         <span class="headingEndMark">
          —
         </span>
         We typically give three courses of
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         3 g/m
         <sup>
          2
         </sup>
         administered over three hours twice per day on days 1, 3, and 5 for a total of six doses per course [
         <a href="#rid26">
          26
         </a>
         ]. Patients older than 60 years typically receive 2 g/m
         <sup>
          2
         </sup>
         and those older than 70 years 1.5 g/m
         <sup>
          2
         </sup>
         . The initial course is begun after confirmation of a complete remission and resolution of all toxicities from induction therapy. Sequential courses are administered no sooner than every 28 days or 1 week after marrow recovery as documented by an absolute neutrophil count ≥1000 and platelets ≥100,000 without transfusion.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          Saline
         </a>
         or steroid eye drops should be administered to both eyes four times daily until 24 hours after completion of the HiDAC infusion to prevent chemical conjunctivitis due to
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         in the tears. Cerebellar evaluations for dysdiadochokinesis or past-pointing should be performed at least every 12 hours during therapy.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Toxicities
         </span>
         <span class="headingEndMark">
          —
         </span>
         This regimen is usually administered as an inpatient and requires close monitoring for toxicities. Even within the context of a clinical trial, only approximately 56 percent of patients under age 60 were able to complete four courses of this regimen. Treatment related mortality, mostly due to infection, is approximately 5 percent. Common major side effects of HiDAC include pancytopenia, infection (62 percent), central nervous system toxicity (13 percent), hyperbilirubinemia (11 percent), and fatigue (10 percent) [
         <a href="#rid22">
          22,26
         </a>
         ].
        </p>
        <p>
         Of particular importance, serious central nervous system toxicities (eg, somnolence and confusion, and rarely seizures, cerebral dysfunction, and acute cerebellar syndrome) can be seen in approximately 12 percent of patients overall. This percentage rises to approximately 30 percent in patients over the age of 60, 40 percent of whom may be left with permanent disability. If cerebellar toxicity occurs,
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         should be discontinued. The clinical situation can be confusing if patients are also receiving anti-emetics or other drugs that can have CNS effects. It is unclear whether patients should be rechallenged with HiDAC in the future.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          INTERMEDIATE-RISK DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Post-remission therapy options for patients with intermediate-risk disease include consolidation chemotherapy with high dose
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         (HiDAC) as given for favorable-risk disease, HiDAC followed by autologous hematopoietic cell transplantation (HCT), or allogeneic HCT alone:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consolidation chemotherapy with HiDAC is nonmyeloablative and has a low treatment-related mortality rate (approximately 5 percent). Rates of four-year disease-free survival among patients with intermediate-risk disease are approximately 30 percent [
         <a href="#rid29">
          29
         </a>
         ]. Common major side effects include pancytopenia, infection, central nervous system toxicity, and hyperbilirubinemia [
         <a href="#rid22">
          22,26
         </a>
         ]. (See
         <a class="local">
          'Toxicities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autologous HCT allows the use of myeloablative chemotherapy and is not associated with graft-versus-host disease, but does not provide the graft-versus-leukemia effect seen with allogeneic HCT [
         <a href="#rid30">
          30-37
         </a>
         ]. Treatment-related morbidity and mortality are relatively low (≤6 percent) but relapse rates are high (30 to 50 percent) [
         <a href="#rid38">
          38-42
         </a>
         ]. Rates of four-year disease-free survival are approximately 45 percent and are in the same range as those in patients who receive intensive but nonablative consolidation chemotherapy (eg, HiDAC) [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Allogeneic HCT targets cancer cells both by administering myeloablative chemotherapy and by harnessing a graft-versus-leukemia effect. Treatment-related mortality is high (approximately 20 percent) as is morbidity associated with graft-versus-host disease [
         <a href="#rid7">
          7
         </a>
         ]. Rates of four-year disease-free survival are approximately 48 percent overall; patients younger than 35 or 40 years have superior results [
         <a href="#rid7">
          7,43,45
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Three large meta-analyses of prospective studies comparing these post-remission therapies for patients with AML, subdivided by karyotypes, have been performed using data from over 4000 patients with AML in first complete remission (CR) [
         <a href="#rid6">
          6-8
         </a>
         ]. There were 603 patients with intermediate-risk disease analyzed. In an intention-to-treat analysis, patients "genetically assigned" to matched related donor HCT (ie, those who had an HLA-matched sibling) had superior rates of four-year disease-free survival. While overall survival did not reach statistical significance in the first meta-analysis, combination of the data from these three meta-analyses demonstrated a benefit in overall survival implying that allogeneic HCT was beneficial for patients in this risk group overall. Such results were particularly noticeable for patients younger than age 35 years who tolerate the morbidity from HCT better.
        </p>
        <p>
         A decision regarding the use of allogeneic HCT in first CR must also consider the estimated rate of relapse and the efficacy of available treatments at the time of relapse. In one analysis, 1337 of 2029 younger adults (16 to 49 years) with intermediate-risk AML enrolled on prospective trials did not proceed with HCT in first CR [
         <a href="#rid10">
          10
         </a>
         ]. Of these, 780 (58 percent) relapsed with an estimated five-year survival following relapse of 17 percent. Among patients with relapsed disease, survival was superior for the 326 patients who underwent allogeneic HCT after relapse (47 versus 15 percent). In this particular (time-dependent) analysis, there was a similar difference in survival outcome for patients who had allogeneic HCT in first CR and for those who did not undergo HCT in first CR but underwent a late HCT for salvage after relapse of leukemia.
        </p>
        <p>
         The choice of post-remission therapy for an individual with intermediate-risk disease depends on the patient's age and comorbidities. Advances in conditioning regimens (eg, non-myeloablative or reduced intensity conditioning) and alternative donor sources (eg, umbilical cord blood, haploidentical donors) have increased the number of patients with intermediate-risk disease who are candidates for allogeneic HCT [
         <a href="#rid46">
          46
         </a>
         ]. Age and comorbidities are host factors that define the mortality risk of the transplant and which can be taken into account in relation to the risk of relapse of the disease. As an example, young patients (eg, &lt;40 years old) with few comorbidities may choose allogeneic HCT rather than autologous HCT or HiDAC. This preference places a strong emphasis on the survival benefit seen on meta-analysis and a lesser emphasis on the high rate of treatment related mortality and morbidity. A post-remission treatment calculator has been proposed that incorporates age, percentage of CD34 positive blasts,
         <em>
          FLT3
         </em>
         -ITD mutant-to-wild-type ratio, cytogenetic risk, and disease status to predict probability of survival with these therapies [
         <a href="#rid47">
          47
         </a>
         ]. However,
         <em>
          FLT3
         </em>
         -ITD mutant-to-wild-type ratio is not widely available and measures of CD34-positive blasts may have variability among institutions [
         <a href="#rid48">
          48
         </a>
         ]. As such, we await validation of this calculator in other cohorts prior to its widespread application.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          UNFAVORABLE-RISK DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with unfavorable-risk cytogenetics or molecular genetics (especially those age &lt;40 years), we recommend allogeneic hematopoietic cell transplantation (HCT) rather than autologous HCT or consolidation chemotherapy alone. Furthermore, we suggest myeloablative conditioning rather than reduced intensity or nonmyeloablative conditioning. Enrollment in a clinical trial is advised if a related or unrelated donor is not available or if the patient is not a candidate for transplantation.
        </p>
        <p>
         Patients with unfavorable karyotypes, as defined above, do poorly when treated with consolidation chemotherapy alone after attainment of a complete remission; rates of five-year overall survival with this approach are 15 to 30 percent [
         <a href="#rid2">
          2,3,7,10,29
         </a>
         ]. In contrast, treatment with allogeneic HCT provides an additional graft-versus-leukemia (GVL) effect together with myeloablative chemotherapy, resulting in superior survival rates of approximately 40 percent at four years [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         The strong GVL response in AML is illustrated by the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rates of AML relapse are much higher in patients who have received identical twin (syngeneic) transplants compared with HLA-identical sibling transplants administered with identical cytotoxic treatment (eg, 52 versus 16 percent in one series) [
         <a href="#rid49">
          49
         </a>
         ]; this difference relates to the allogeneic GVL effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who relapse after an allogeneic HCT may benefit from donor lymphocyte infusion (DLI). As an example, remission was achieved with DLI in 29 percent in one study of 23 patients [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Unfortunately, the beneficial GVL response is closely associated with acute and chronic graft-versus-host disease (GVHD), while intensive myeloablative chemotherapy is associated with life-threatening cytopenias. Both are major causes of morbidity and mortality following allogeneic HCT. GVHD can be reduced by T cell depletion from the donor marrow, generally at the risk of increased rates of graft failure and leukemia relapse. (See
         <a class="medical medical_review" href="/z/d/html/3542.html" rel="external">
          "Prevention of graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
         In order to offer these patients the best chance of a successful HCT before relapse, planning for HCT should begin as early as possible with HLA typing and a donor search. (See
         <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">
          "Donor selection for hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Myeloablative allogeneic transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several prospective studies have evaluated different post-remission strategies in patients with unfavorable-risk disease [
         <a href="#rid30">
          30,51-56
         </a>
         ]. Investigators have generally relied on a "genetic randomization" in which patients are assigned to treatment with or without allogeneic HCT based on the presence or absence of an HLA-matched sibling donor. The strength of evidence provided by these observational studies is limited by a lack of true randomization. (See
         <a class="local">
          'Chemotherapy versus transplantation'
         </a>
         above.)
        </p>
        <p>
         Three large meta-analyses of these observational studies performed using data from patients with AML in first complete remission examined the effect of patient age, donor availability and cytogenetic risk category on disease-free and overall survival [
         <a href="#rid6">
          6-8
         </a>
         ]. Patients with unfavorable-risk disease who had an HLA-matched sibling donor had the following significant outcomes when compared with patients assigned to treatment with chemotherapy with or without autologous HCT, when analyzed in an intention-to-treat fashion:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Superior rates of four-year overall survival (40 versus 30 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improved rates of disease-free survival at four years (33 versus 17 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fewer relapses at four years (39 versus 77 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher treatment-related mortality (28 versus 6 percent)
        </p>
        <p>
        </p>
        <p>
         Further analysis using age cutoffs of either 35 or 40 years found that younger patients have a lower treatment-related mortality and, as a result, the benefits of allogeneic HCT become more pronounced.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Conditioning regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allogeneic HCT should be delivered shortly after attainment of an initial complete remission. Post-remission consolidation therapy with standard or high-dose
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         is not associated with improved outcome, compared with proceeding directly to allogeneic transplantation following successful induction therapy [
         <a href="#rid57">
          57,58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3557.html" rel="external">
          "Preparative regimens for hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
         The ideal conditioning (preparative) regimen is unknown and clinical practice differs by institution according to experience. Conditioning regimens have variable intensity, toxicity, and dependence on a graft-versus-tumor effect  (
         <a class="graphic graphic_figure graphicRef87814" href="/z/d/graphic/87814.html" rel="external">
          figure 1
         </a>
         ). The terms myeloablative conditioning (MAC), nonmyeloablative (NMA) conditioning, and reduced intensity conditioning (RIC) have been used with variable definitions and the dividing lines between these categories are not clear. In addition, the ability of individuals to tolerate the toxicities associated with these regimens has improved with advances in supportive care (eg, antifungal agents, CMV prophylaxis, GVHD prophylaxis).
        </p>
        <p>
         For most younger adults (&lt;40 years) undergoing allogeneic HCT, we suggest MAC rather than RIC or NMA conditioning. Randomized trials suggest that, when compared with MAC, the less intensive regimens (NMA/RIC) are associated with a modest decrease in transplant-related mortality, but higher relapse rates and comparable overall survival, as described in greater detail below. (See
         <a class="local">
          'NMA/RIC versus MAC regimens'
         </a>
         below.)
        </p>
        <p>
         For patients who are not candidates for MAC, these less intensive regimens may offer higher rates of leukemia-free survival when compared with consolidation chemotherapy alone. RIC and NMA are discussed in more detail separately. (See
         <a class="local">
          'Nonmyeloablative/reduced intensity HCT'
         </a>
         below.)
        </p>
        <p>
         MAC regimens include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          Busulfan
         </a>
         and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (Bu/Cy) [
         <a href="#rid59">
          59
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          Busulfan
         </a>
         and
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         (Bu/Flu) [
         <a href="#rid60">
          60
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          Fludarabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         140 mg/m
         <sup>
          2
         </sup>
         (Flu/Mel) [
         <a href="#rid61">
          61,62
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          Melphalan
         </a>
         ,
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         , and total body irradiation (TBI) [
         <a href="#rid63">
          63
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          Cyclophosphamide
         </a>
         plus TBI (Cy/TBI) [
         <a href="#rid59">
          59,64
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Retrospective and observational studies suggest that myeloablative conditioning with intravenous Bu/Cy results in superior survival rates when compared with Cy/TBI. Many centers prefer intravenous
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         to oral busulfan because of the better and more predictable pharmacokinetics.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective analysis from the Center for International Blood and Marrow Transplantation Research (CIBMTR) included 1230 patients with AML in first complete remission who underwent sibling or matched unrelated donor HCT following conditioning with Cy/TBI (586 patients), oral Bu/Cy (408 patients), or intravenous Bu/Cy (236 patients) from 2000 to 2006 [
         <a href="#rid65">
          65
         </a>
         ]. When compared with Cy/TBI, intravenous Bu/Cy (but not oral Bu/Cy) resulted in less nonrelapse mortality (relative risk [RR] 0.58; 95% CI 0.39-0.86), better leukemia-free survival (RR 0.70; 95% CI 0.55-0.88), and better overall survival (RR 0.68; 95% CI 0.52-0.88).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A multicenter nonrandomized cohort study reported outcomes following different conditioning regimens for patients with myeloid malignancies (40 percent AML in first complete remission) undergoing sibling or unrelated donor HCT [
         <a href="#rid66">
          66
         </a>
         ]. When compared with the 458 patients who received Cy/TBI, the 1025 patients who received intravenous Bu/Cy demonstrated superior survival (RR 0.82; 95% CI 0.68-0.98). Rates of relapse and treatment-related mortality were similar between the two groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an unblinded multicenter phase III trial, 252 adults (age 40 to 65 years) with AML in first remission were randomly assigned to receive Bu/Cy or the same myeloablative dose of
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         plus
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         [
         <a href="#rid60">
          60
         </a>
         ]. After a median follow-up of 28 months, Bu/Cy resulted in greater estimated two-year nonrelapse mortality (18 versus 10 percent), but the estimated rates of relapse (30 versus 32 percent) and overall survival (64 versus 62 percent) at two years were similar.
        </p>
        <p>
        </p>
        <p>
         Additional issues related to the choice of conditioning regimen are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3557.html" rel="external">
          "Preparative regimens for hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Choice of donor
         </span>
         <span class="headingEndMark">
          —
         </span>
         All of the prospective trials evaluating allogeneic HCT in first complete remission included in the meta-analyses mentioned above used HLA-matched related donors since this criterion was used as the method for treatment stratification. However, only 25 to 30 percent of potential recipients have HLA-matched siblings who can serve as donors. With the advent of molecular typing techniques, morbidity and mortality associated with the use of HLA-matched unrelated donors has declined. (See
         <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">
          "Donor selection for hematopoietic cell transplantation", section on 'Unrelated donors'
         </a>
         .)
        </p>
        <p>
         For patients without an HLA-matched sibling, the following donors may be considered since they are expected to result in similar outcomes [
         <a href="#rid67">
          67-79
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Matched unrelated donor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Single antigen mismatched related donor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Umbilical cord blood transplantation
        </p>
        <p>
        </p>
        <p>
         Allogeneic HCT using a matched unrelated donor (MUD) is an option for younger adults who lack a sibling donor. The likelihood of finding a MUD in the National Bone Marrow Donor Registry is related in part to the ethnic background of the patient compared with the volunteer donor pool. It also depends on the number of allelic mismatches between donor and recipient that one wishes to allow (eg, a full 10/10 match or 9/10 or 8/10 with mismatches). The overall match rate is approximately 50 percent for White Americans but only 10 percent for racial/ethnic underrepresented groups who are both underrepresented in the donor pool and more polymorphic with respect to HLA [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
         Due to the relative immaturity of the immune system in umbilical cord samples, stem cells from this source allow the crossing of immunologic barriers that would otherwise be prohibitive. As a result, the degree of HLA-disparity that is tolerable is much greater, making this approach more feasible for members of underrepresented groups. In addition, cord blood has already been collected and cryopreserved before the time a match is identified, thereby greatly reducing the time required for accessing the donor and completing the transplant procedure; however, there is less clinical follow-up with cord blood transplantations and long term follow-up will be necessary to determine whether they truly provide equivalent results [
         <a href="#rid73">
          73,81
         </a>
         ].
        </p>
        <p>
         Another option which would significantly increase donor availability is to use T cell depleted stem cells from related donors with one fully mismatched HLA haplotype, sometimes called partially-matched family member transplants or haploidentical transplants [
         <a href="#rid82">
          82-85
         </a>
         ]. This method should be considered as investigational as only limited data in selected patients are available and this procedure is associated with severe and prolonged immunodeficiency after transplantation. (See
         <a class="medical medical_review" href="/z/d/html/96032.html" rel="external">
          "HLA-haploidentical hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Nonmyeloablative/reduced intensity HCT
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend myeloablative conditioning (MAC) regimens rather than nonmyeloablative (NMA) or reduced intensity conditioning (RIC) preparative regimens for patients with unfavorable risk AML who are candidates for HCT. (See
         <a class="local">
          'Conditioning regimen'
         </a>
         above.)
        </p>
        <p>
         We generally offer NMA/RIC conditioning regimens rather than autologous HCT or consolidation chemotherapy alone for patients with unfavorable risk AML who are not considered eligible for MAC regimens (eg, based on advanced age or co-morbid conditions). For such patients, NMA/RIC allogeneic HCT may offer higher rates of leukemia-free survival when compared with consolidation chemotherapy alone [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
         NMA and RIC preparative regimens were developed as an alternative strategy for allogeneic HCT because MAC may lead to significant early morbidity and mortality in older patients and those with comorbid medical conditions. These procedures rely less on the dose intensity of the pretransplant cytotoxic regimen and depend heavily upon the graft-versus-leukemia response [
         <a href="#rid67">
          67,87-92
         </a>
         ]. For this approach to achieve long-term disease-free survival, it seems likely that a durable complete remission must first be achieved before HCT.
        </p>
        <p>
         Preparative regimens for HCT have variable intensity, toxicity, and dependence upon a graft-versus-tumor effect  (
         <a class="graphic graphic_figure graphicRef87814" href="/z/d/graphic/87814.html" rel="external">
          figure 1
         </a>
         ). Eligibility criteria for NMA/RIC allogeneic HCT and choice of preparative regimen are generally determined by the transplant center. General eligibility criteria, definitions, and examples of MAC, NMA, and RIC preparative regimens are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/3557.html" rel="external">
          "Preparative regimens for hematopoietic cell transplantation", section on 'Definitions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16870.html" rel="external">
          "Determining eligibility for allogeneic hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1914200632">
         <span class="h3">
          NMA/RIC versus MAC regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Trials that randomly assigned patients to NMA/RIC versus MAC preparative regimens have reported that the less intensive regimens are associated with higher rates of relapse, but a modest decrease in transplant-related mortality (TRM); these offsetting effects have generally resulted in comparable overall survival (OS). The following phase 3 trials have compared MAC versus NMA/RIC regimens for AML:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A multicenter trial that randomly assigned 272 adults with AML or MDS (18 to 65 years old) in morphologic CR was closed early after review by the Data and Safety Monitoring Board suggested a benefit for MAC over RIC [
         <a href="#rid93">
          93
         </a>
         ]. Compared with RIC, MAC was associated with superior relapse-free survival (RFS; 68 versus 47 percent, respectively), but a higher rate of TRM (16 versus 4 percent); as a result, there was no difference in OS at 18 months. A subsequent analysis of this trial reported that the benefits of MAC were confined to the approximately two-thirds of patients who had measurable residual disease (MRD) prior to transplantation. A next-generation sequencing (NGS)-based assay was used to detect mutations with a minimum allele frequency of 0.001 in 13 genes associated with AML [
         <a href="#rid94">
          94
         </a>
         ]. No mutations were detected in 32 percent of MAC and 37 percent of RIC recipients; for these MRD-negative patients, there was no difference in outcomes between conditioning regimens (ie, 56 versus 63 percent three-year OS, respectively). For MRD-positive patients, compared with RIC, those who underwent MAC had a more favorable three-year cumulative incidence of relapse (19 percent versus 67 percent, respectively) and superior three-year OS (61 versus 43 percent). In multivariate analysis of NGS-positive patients, after adjusting for disease risk and donor group, RIC was associated with an increased risk for relapse (hazard ratio [HR], 6.4; 95% CI 3.4 to 12.1), decreased RFS (HR, 2.9; 95% CI 1.8-4.7), and decreased OS (HR, 2.0; 95% CI 1.2 to 3.3).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A multicenter trial randomly assigned 195 younger adults (age ≤60 years) with intermediate-risk or high-risk AML in first complete remission who had an available HLA-matched sibling or matched unrelated donor to MAC or RIC, each followed by allogeneic HCT [
         <a href="#rid95">
          95
         </a>
         ]. The trial closed early due to poor accrual and thus has limited statistical power. When compared with RIC, MAC was associated with similar estimated rates at three years of OS (58 versus 61 percent, respectively), nonrelapse mortality (NRM; 18 versus 13 percent), and rates of relapse (26 versus 28 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another phase 3 trial reported that among 129 patients, RIC and MAC were associated with comparable two-year RFS and OS [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3273878443">
         <span class="h3">
          NMA/RIC versus chemotherapy consolidation
         </span>
         <span class="headingEndMark">
          —
         </span>
         RIC or NMA conditioning is feasible in a subset of patients who are not candidates for MAC HCT. For such patients with intermediate- or unfavorable-risk disease in first complete remission, we suggest RIC or NMA conditioning followed by related or unrelated donor HCT rather than consolidation chemotherapy alone.
        </p>
        <p>
         The following studies illustrate the efficacy of RIC and NMA in patients who are not candidates for MAC:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A single center prospective trial compared outcomes with a RIC allogeneic HCT versus consolidation chemotherapy in 95 patients with intermediate-risk (80 percent) or unfavorable-risk AML in first complete remission [
         <a href="#rid86">
          86
         </a>
         ]. All patients were considered to be candidates for RIC, and "genetic randomization" was used to assign treatment with or without allogeneic HCT based on the presence or absence of an HLA-matched sibling donor. At a median follow-up of 4.8 years, patients with an HLA-matched sibling donor had significantly higher estimated rates of leukemia-free survival at seven years (60 versus 23 percent). Treatment-related mortality for those who underwent RIC was 12 percent [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective study employed NMA conditioning using 2 Gy total body radiation with or without
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         in 122 patients with AML, most of whom were considered ineligible for conventional allogeneic HCT because of older age or comorbidities [
         <a href="#rid91">
          91
         </a>
         ]. The median age was 58 years (range: 17 to 74). At a median follow-up of 44 months, rates of OS were 51 and 61 percent for patients transplanted in first or second complete remission, respectively, and 28 percent for those beyond second complete remission at the time of HCT. Two-year incidences of NRM were 10 and 22 percent for those with related or unrelated donors, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         RIC with a
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         /
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         regimen incorporating
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         was utilized in 76 patients with high-risk AML or MDS, 42 of whom were in first, second, or third complete remission [
         <a href="#rid90">
          90
         </a>
         ]. Median age was 52 years (range: 18 to 71 years). Estimated three-year disease-free survival was 42 percent for those in complete remission at the time of HCT. One-year transplant-related mortality was 19 percent.
        </p>
        <p>
        </p>
        <p>
         If feasible, we suggest the use of a reduced intensity or nonmyeloablative conditioning followed by related or unrelated donor HCT rather than consolidation chemotherapy for older patients with intermediate- or unfavorable-risk AML who are not candidates for myeloablative allogeneic HCT. Ideally this treatment should be performed within the context of a clinical trial to allow for the collection of additional data regarding its safety and efficacy.
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          POST-CONSOLIDATION MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following the completion of post-remission therapy, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends on the comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up.
        </p>
        <p>
         Maintenance therapy alone, using relatively nonmyelosuppressive doses of cytotoxic drugs following remission induction, has no proven benefit in the cure of AML. For patients under 60 years of age, consolidation therapy results in significantly longer survival than maintenance therapy alone. Clinical trials are investigating the use of agents such as interleukin 2,
         <a class="drug drug_general" data-topicid="8855" href="/z/d/drug information/8855.html" rel="external">
          decitabine
         </a>
         , or
         <a class="drug drug_general" data-topicid="112991" href="/z/d/drug information/112991.html" rel="external">
          midostaurin
         </a>
         as a maintenance therapy [
         <a href="#rid98">
          98,99
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Monitoring for relapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to patient surveillance is to schedule patient visits every one to two months for the first two years when the disease is most likely to relapse, and then every three to six months for up to five years post-consolidation. At these visits we perform a complete blood count including platelets, white blood cell differential, and review of the peripheral blood smear. Bone marrow biopsy and aspirate is not routinely performed, but is indicated if the peripheral smear demonstrates abnormalities or if cytopenias develop.
        </p>
        <p>
         The use of measurable residual disease (MRD; also referred to as minimal residual disease) monitoring in patients with AML is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4525.html" rel="external">
          "Acute myeloid leukemia: Induction therapy in medically fit adults", section on 'Monitoring'
         </a>
         .)
        </p>
        <p>
         Treatment of the patient with AML who has relapsed after attainment of a complete remission is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4540.html" rel="external">
          "Treatment of relapsed or refractory acute myeloid leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Monitoring for treatment complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-term treatment complications differ based on the post-remission treatment strategy used. Immunizations and general health maintenance guidelines are recommended.
        </p>
        <p class="headingAnchor" id="H1509717201">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116628.html" rel="external">
          "Society guideline links: Acute myeloid leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29039287">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15854.html" rel="external">
          "Patient education: Autologous bone marrow transplant (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/117867.html" rel="external">
          "Patient education: Allogeneic bone marrow transplant (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/681.html" rel="external">
          "Patient education: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/686.html" rel="external">
          "Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Description
         </strong>
         – Most adults with acute myeloid leukemia (AML) achieve a complete remission (CR) with intensive induction chemotherapy, but virtually all will relapse within months without post-remission therapy. Post-remission management is informed by the risk of relapse, medical fitness, and the patient's values and preferences.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk stratification
         </strong>
         – We stratify risk of relapse according to the European LeukemiaNet (ELN) model  (
         <a class="graphic graphic_table graphicRef111588" href="/z/d/graphic/111588.html" rel="external">
          table 2
         </a>
         ), which considers cytogenetic/molecular features and measurable residual disease (MRD) (see
         <a class="local">
          'Risk stratification'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Favorable features
         </strong>
         – Examples include t(8;21), inv(16), or t(16;16), and MRD-negative patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intermediate features
         </strong>
         – Cytogenetic features that are neither favorable nor adverse or MRD-positive patients
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adverse features
         </strong>
         – Examples include: complex karyotype; monosomal karyotype (eg, -5, del(5q), -7, –17/abn(17p)); t(9;22)/
         <em>
          BCR::ABL1
         </em>
         ; t(6;9)/
         <em>
          DEK::NUP214
         </em>
         ;
         <em>
         </em>
         t(v;11q23.3)/
         <em>
          KMT2A
         </em>
         rearranged; inv(3) or t(3;3)/
         <em>
          GATA2,MECOM
         </em>
         ; FLT3-ITD-high with wild-type NPM1; mutated
         <em>
          RUNX1
         </em>
         ,
         <em>
          ASXL1
         </em>
         , or
         <em>
          TP53.
         </em>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Favorable risk
         </strong>
         – For patients with favorable cytogenetics, we recommend consolidation chemotherapy, rather than allogeneic hematopoietic cell transplantation (HCT) (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Favorable-risk disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intermediate risk
         </strong>
         – For patients with intermediate risk, we consider either consolidation chemotherapy or allogeneic HCT acceptable; the choice of approach is guided by medical fitness, age, availability of a suitable graft donor, and patient preference. (See
         <a class="local">
          'Intermediate-risk disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse risk
         </strong>
         – For patients with adverse risk, we suggest allogeneic HCT for patients with adequate medical fitness and a suitable graft donor. Management is individualized for others. (See
         <a class="local">
          'Unfavorable-risk disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Consolidation chemotherapy
         </strong>
         – Stratified according to age (see
         <a class="local">
          'Choice of agent'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          &lt;60 years
         </strong>
         – We favor three or four cycles of high-dose
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         (HiDAC; eg, 3 g/m
         <sup>
          2
         </sup>
         over 3 hours every 12 hours on days 1, 3, 5 of each cycle).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="8968" href="/z/d/drug information/8968.html" rel="external">
          Gemtuzumab ozogamicin
         </a>
         (for CD33-positive) or
         <a class="drug drug_general" data-topicid="112991" href="/z/d/drug information/112991.html" rel="external">
          midostaurin
         </a>
         (for FLT3-mutated) may be added in selected cases, as discussed above.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          ≥60 years
         </strong>
         – We favor standard-dose
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         (eg, 200 mg/m
         <sup>
          2
         </sup>
         by continuous infusion 1 g/m
         <sup>
          2
         </sup>
         every 12 hours on days 1, 3, and 5) for four cycles.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Allogeneic HCT
         </strong>
         – For most younger adults (&lt;40 years) undergoing allogeneic HCT, we suggest myeloablative conditioning rather than reduced intensity conditioning (RIC) or nonmyeloablative (NMA) conditioning (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). In contrast, RIC or NMA conditioning followed by allogeneic HCT is preferred over consolidation chemotherapy for eligible patients with unfavorable-risk cytogenetics who are not candidates for myeloablative conditioning. (See
         <a class="local">
          'Nonmyeloablative/reduced intensity HCT'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maintenance therapy
         </strong>
         – Maintenance therapy can be given after either consolidation chemotherapy or HCT if a targetable mutation is present, as discussed above. (See
         <a class="local">
          'Post-consolidation management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
         – Surveillance for relapse and treatment-related adverse effects is described above. (See
         <a class="local">
          'Post-consolidation management'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Cassileth PA, Harrington DP, Hines JD, et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 1988; 6:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58:4173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92:2322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011; 29:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005; 103:1652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109:3658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301:2349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79:1924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burnett AK, Goldstone A, Hills RK, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol 2013; 31:1293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcucci G, Maharry K, Whitman SP, et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2007; 25:3337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Röllig C, Bornhäuser M, Kramer M, et al. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. J Clin Oncol 2015; 33:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlenk RF, Taskesen E, van Norden Y, et al. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood 2013; 122:1576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rees JK, Gray RG, Wheatley K. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party. Br J Haematol 1996; 94:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer 2006; 107:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood 2011; 117:2366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas X, Elhamri M, Raffoux E, et al. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood 2011; 118:1754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaich M, Parmentier S, Kramer M, et al. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol 2013; 31:2094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaich M, Röllig C, Soucek S, et al. Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol 2011; 29:2696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013; 31:3360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 2005; 105:3420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas X, de Botton S, Chevret S, et al. Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. J Clin Oncol 2017; 35:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradstock KF, Link E, Di Iulio J, et al. Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. J Clin Oncol 2017; 35:1678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 2013; 121:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331:896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999; 17:3767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrd JC, Ruppert AS, Mrózek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 2004; 22:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88:2841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339:1649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ball ED, Rybka WB. Autologous bone marrow transplantation for adult acute leukemia. Hematol Oncol Clin North Am 1993; 7:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linker CA, Ries CA, Damon LE, et al. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplant 1998; 22:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Löwenberg B. Post-remission treatment of acute myelogenous leukemia. N Engl J Med 1995; 332:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). Blood 1997; 90:2978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorin NC, Labopin M, Pichard P, et al. Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells. Br J Haematol 2000; 110:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazarus HM, Pérez WS, Klein JP, et al. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol 2006; 132:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsimberidou AM, Stavroyianni N, Viniou N, et al. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 2003; 97:1721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan PC, Sung L, Crump M, Beyene J. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst 2004; 96:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loh YS, Koh LP, Tai BC, et al. Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation. Leuk Lymphoma 2007; 48:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farag SS, Ruppert AS, Mrózek K, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol 2005; 23:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vellenga E, van Putten W, Ossenkoppele GJ, et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011; 118:6037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmid C, Labopin M, Socié G, et al. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood 2015; 126:2062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 2016; 127:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfirrmann M, Ehninger G, Thiede C, et al. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol 2012; 13:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrara F. Renaissance of autologous stem cell transplantation for AML? Lancet Oncol 2012; 13:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86:2041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keating S, de Witte T, Suciu S, et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Br J Haematol 1998; 102:1344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frassoni F, Labopin M, Gluckman E, et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant 1996; 17:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blaise D, Maraninchi D, Michallet M, et al. Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood 2001; 97:3669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greinix HT, Nachbaur D, Krieger O, et al. Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. Br J Haematol 2002; 117:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stelljes M, Krug U, Beelen DW, et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol 2014; 32:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tallman MS, Rowlings PA, Milone G, et al. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 2000; 96:1254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeshurun M, Labopin M, Blaise D, et al. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer 2014; 120:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagler A, Rocha V, Labopin M, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol 2013; 31:3549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rambaldi A, Grassi A, Masciulli A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2015; 16:1525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baron F, Labopin M, Peniket A, et al. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer 2015; 121:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryant A, Nivison-Smith I, Pillai ES, et al. Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients. Bone Marrow Transplant 2014; 49:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murata M, Nishida T, Haneda M, et al. A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. Br J Haematol 1999; 105:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bacigalupo A, Vitale V, Corvò R, et al. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol 2000; 108:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Copelan EA, Hamilton BK, Avalos B, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood 2013; 122:3863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bredeson C, LeRademacher J, Kato K, et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood 2013; 122:3871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ringdén O, Labopin M, Ehninger G, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27:4570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore J, Nivison-Smith I, Goh K, et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007; 13:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valcarcel D, Kan F, Wang T, et al. One antigen HLA-mismatched related and 8/8 allele matched unrelated donors are associated with similar survival after hematopoietic cell transplantation for acute leukemia (abstract). Blood 2008; 112:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Appelbaum FR. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia when a matched related donor is not available. Hematology Am Soc Hematol Educ Program 2008; :412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351:2276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schetelig J, Bornhäuser M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008; 26:5183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atsuta Y, Suzuki R, Nagamura-Inoue T, et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 2009; 113:1631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basara N, Schulze A, Wedding U, et al. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia 2009; 23:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter RB, Pagel JM, Gooley TA, et al. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia 2010; 24:1276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta V, Tallman MS, He W, et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010; 116:1839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlenk RF, Döhner K, Mack S, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 2010; 28:4642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang XJ, Zhu HH, Chang YJ, et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 2012; 119:5584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunstein CG, Eapen M, Ahn KW, et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012; 119:5591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mori M, Beatty PG, Graves M, et al. HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation 1997; 64:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee KH, Lee JH, Lee JH, et al. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood 2011; 118:2609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23:3447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008; 112:3574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Liu QF, Xu LP, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 2015; 125:3956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohty M, de Lavallade H, Ladaique P, et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 2005; 19:916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blaise DP, Michel Boiron J, Faucher C, et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 2005; 104:1931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong R, Giralt SA, Martin T, et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003; 102:3052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stelljes M, Bornhauser M, Kroger M, et al. Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood 2005; 106:3314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23:9387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson RP Jr, Yu M, Schwartz JE, et al. Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia. Bone Marrow Transplant 2010; 45:1300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott BL, Pasquini MC, Logan BR, et al. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol 2017; 35:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hourigan CS, Dillon LW, Gui G, et al. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. J Clin Oncol 2020; 38:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bornhäuser M, Kienast J, Trenschel R, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol 2012; 13:1035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kröger N, Iacobelli S, Franke GN, et al. Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). J Clin Oncol 2017; 35:2157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohty M, de Lavallade H, El-Cheikh J, et al. Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison. Leukemia 2009; 23:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buyse M, Squifflet P, Lange BJ, et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood 2011; 117:7007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood 2019; 133:840.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4533 Version 51.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3282032" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9751631" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9746770" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27895058" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21172891" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15742336" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17213292" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19509382" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1562720" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Varying intensity of postremission therapy in acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23439754" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17577018" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18450602" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25547501" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23863898" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8757514" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16721819" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21190996" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21690555" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23630210" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21606413" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Cytarabine dose of 36 g/m²compared with 12 g/m²within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23940227" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15572587" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28221862" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28368672" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23287624" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8078551" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10577848" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15020610" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8874180" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9834301" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8449859" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Autologous bone marrow transplantation for adult acute leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9827814" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7808487" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7808494" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Post-remission treatment of acute myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9504514" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9376578" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11054076" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16487177" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11133742" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12655529" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14709737" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17325850" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15534356" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21951683" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26351297" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26660427" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Hematopoietic stem cell transplantation for patients with AML in first complete remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22197676" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22197675" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Renaissance of autologous stem cell transplantation for AML?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2297567" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Graft-versus-leukemia reactions after bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7655033" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9753069" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8673048" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11392326" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12060131" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12714526" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24366930" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10942365" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24338939" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23980086" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26429297" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25424330" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24056743" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10354150" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10651732" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24065243" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24081656" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19652066" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17448920" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : One antigen HLA-mismatched related and 8/8 allele matched unrelated donors are associated with similar survival after hematopoietic cell transplantation for acute leukemia (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19074118" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Allogeneic hematopoietic cell transplantation for acute myeloid leukemia when a matched related donor is not available.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15564544" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18768435" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19104080" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19151786" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20485378" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20538804" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20805454" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22535659" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22496153" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9381524" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20558104" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21715313" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15753458" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18606875" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25940714" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15843817" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16178004" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12842990" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16020510" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16314618" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16344316" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20062092" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28380315" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31860405" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22959335" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28463633" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18580956" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21518931" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30563875" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
